A cross model spatial and single-cell atlas reveals the conserved involvement of osteopontin in polycystic kidney disease
Sarah Jane MilleriD, Hua ZhongiD, Weidong Wu, Audrey M. CordovaiD, Morgan E. YashchenkoiD, Alex YashchenkoiD, Zhang LiiD, Daniyal J. JafreeiD, Chelsea N. Zimmerman, Christa I. DeVetteiD, Vicki DoiD, Maya Hignite, Yohan ParkiD, Fariha NusratiD, Dr Bibi Maryam, Sizhao LuiD, Xiaoyan Li, Jenny R. Gipson, Xiaogang LiiD, David Andrew LongiD, Mary C.M. Weiser‐EvansiD, Bradley K. YoderiD, Benjamin D. CowleyiD, Katharina HoppiD, Jason R. StubbsiD, , Kurt A. ZimmermaniD
Abstract
Polycystic kidney disease (PKD) arises from mutations in cilia-associated genes, such as PKD1 and PKD2, expressed in renal epithelial cells, leading to progressive kidney dysfunction and end- stage kidney disease (ESKD). PKD patients exhibit significant heterogeneity in disease progression, largely due to genetic and environmental modifiers. Like patients, mouse models of PKD also exhibit significant heterogeneity with regards to the gene mutated, age of disease onset, and rate of disease progression. To elucidate the cellular and molecular consequences of these variables, we constructed an integrated single-cell and spatial transcriptomics atlas across mouse models of PKD, mapping changes in cell type composition, gene expression, and intercellular signaling networks across the whole atlas and within individual models. Consistently across models, single cell RNA sequencing (scRNAseq) data revealed increased Spp1 (osteopontin) expression and signaling from PKD-enriched clusters to Ly6clo monocytes. Global deletion of Spp1 in Pkd1RC/RC mice resulted in reduced cyst severity, improved kidney function, and reduced Ly6clo monocyte numbers, suggesting that SPP1 signaling to Ly6clo monocytes promotes PKD progression. We also created a freely available, searchable website (https://bmblx.bmi.osumc.edu/scPKD/) that can be used to identify cross- and intra-model specific changes in gene expression, guiding researchers to new therapeutic targets for treating PKD.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 0
- FWCI
- 0.00
- Field percentile
- top 45%
- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Multi-omics profiling of mouse polycystic kidney disease progression at a single cell resolution
Yoshiharu Muto, Yasuhiro Yoshimura, … Benjamin D. Humphreys·Proceedings of the National Academy of SciencesPeer-reviewed·Oct 15, 2024
- Defining cellular complexity in human autosomal dominant polycystic kidney disease by multimodal single cell analysis
Yoshiharu Muto, Eryn E. Dixon, … Benjamin D. Humphreys·Nature CommunicationsPeer-reviewed·Oct 30, 2022
- Single-nucleus Transcriptomics Reveals Precystic Dysfunction in Polycystic Kidney Disease
Jonathan Marquez, Oleksandra Tymchyshyna, … David R. Beier·bioRxiv·Jun 25, 2026
- Tubular obstruction induced polycystin upregulation is pro-fibrotic and induced a severe cystic phenotype in adult mice with autosomal dominant polycystic kidney disease: the coexistence of polycystin loss and gain function in ADPKD
Ming Wu, Yanzhe Wang, … Chaoyang Ye·bioRxiv·Nov 3, 2021
- A unique subset of pericystic endothelium associates with aberrant microvascular remodelling and impaired blood perfusion early in polycystic kidney disease
Daniyal J. Jafree, Charith Perera, … David Andrew Long·Disease Models & MechanismsPeer-reviewed·Mar 21, 2025
- c-Jun N-terminal kinase (JNK) signaling contributes to cystic burden in polycystic kidney disease
Abigail O. Smith, Julie A. Jonassen, … Gregory J. Pazour·PLoS GeneticsPeer-reviewed·Dec 28, 2021